AAIPharma bulks up; Teva CEO Yanai to retire;

> AAIPharma is buying equipment and adding a filling line at one North Carolina facility, adding a second work shift at another, and building a 40,000-square-foot lab and technology center at its Wilmington headquarters site. Story | Story

> Teva Pharmaceutical president ($TEVA) and CEO Shlomo Yanai plans to retire in May 2012; Jeremy Levin, formerly with Bristol-Myers Squibb, is expected to succeed him. Teva release

> Athena Drug Delivery Solutions will develop, manufacture and commercialize AtorFen (fenofibrate-atorvastin fixed dose combination), an investigational cholesterol drug from Veloxis Pharmaceuticals, which will get 70% of revenues. News

> Micro Labs has ordered GEA Pharma Systems' Flexstream process technology for spray granulation and pellet coating. Item

> Alarmed over the domestic pharma companies being acquired by multinational Big Pharmas, Indian officials have done away with automatic approvals for foreign direct investment. Report

> A new three-layer heat-sealed plastic film from BASF will protect the active ingredient Kollidon against contact with oxygen, allowing a lower peroxide level of the material. News

> Actavis has named Agility Spain to transport 300 pallets of drugs from a Malta production site to 15 European countries for generics launches. Item

> For sale: A well-established pharmaceutical manufacturing and marketing company available for immediate majority equity acquisition or outright sale in India. Listing


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.